SLC5A2 and heart failure: The significant improvements observed with Dapagliflozin in both short-term and long-term studies, particularly in patients with heart failure with reduced ejection fraction (HFrEF) and non-ischemic dilated cardiomyopathy (NIDCM), further support the role of SGLT-2 inhibitors in cardiac reverse remodeling.